Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

KMTS vs DXR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

KMTS Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 4–6 Matrix Metrics)

KMTS Overall Winner 6-Pillar Tally: KMTS 2 – 2 DXR (2 Tie) Matrix Metrics: KMTS 4 – 6 DXR

As of Nov 16, 2026, Kestra Medical Technologies, Ltd. (KMTS) is the stronger overall head-to-head candidate over Daxor Corporation (DXR) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow). KMTS carries a Unified Composite Score of 43.8/100 (HOLD) at $27.97 (N/M Forward P/E, -134.5% operating margin), whereas DXR carries 52.2/100 (HOLD) at $8.36 (64.5x Forward P/E, -5894.3% operating margin).

  • Composite vs. Pillar Nuance: While DXR currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. KMTS 43.8/100 HOLD), KMTS captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (-134.5% vs. -5894.3% operating margin) and revenue trajectory (+59.9% vs. +25.5% YoY).
  • Technical & Structure Timing Caution: KMTS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.0); meanwhile DXR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About KMTS vs DXR
KMTS NASDAQ Head-to-Head Winner
Kestra Medical Technologies, Ltd. Common Stock
Surgical & Medical Instruments & Apparatus
$27.97
-2.34% 1D
Market Cap $1.7B
TTM Revenue $107M
Forward P/E N/M
Beta / 30D Vol 1.84β · 63% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 21.0 Fund 39.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.0 · SMA20: $29.27 · SMA50: $27.43
DXR NASDAQ
Daxor Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$8.36
-1.47% 1D
Market Cap $49.5M
TTM Revenue $31,360
Forward P/E 64.5x
Beta / 30D Vol 0.28β · 32% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 52.0 Fund 59.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.2%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $8.91 · SMA50: $10.07

6-Pillar Scorecard Institutional Category Breakdown (KMTS 2 – 2 DXR)

Columns: Metric · KMTS · DXR
1. Valuation Multiples DXR
Forward P/E N/M 64.5x
Trailing P/E N/M 7.7x
PEG Ratio N/M N/M
EV / Revenue 15.5x N/M
2. Growth & Scale KMTS
Revenue Growth (YoY) +59.9% +25.5%
Earnings Growth (YoY) +0.0% +329.3%
TTM Revenue (USD) $107M $31,360
Market Cap $1.7B $49.5M
3. Profitability & Quality DXR
Gross Margin 53.9% 100.0%
Operating Margin -134.5% -5894.3%
Net Profit Margin -140.4% 19861.4%
Return on Equity (ROE) -73.7% 14.2%
4. Balance Sheet & Cash Flow KMTS
Cash Generation (TTM) -$117M N/A
Cash Flow Margin -109.7% N/A
Net Cash / Leverage $53M Net Cash $8.88 Book/Sh · 14.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: KMTS (4) vs DXR (6)
Institutional Metric KMTS DXR Criterion Row Edge
Market Capitalization
Scale
$1.7B $49.5M Larger Scale KMTS
Trailing P/E Ratio
Valuation
N/M 7.7x Lower Multiple DXR
Forward P/E Ratio
Valuation
N/M 64.5x Lower Multiple DXR
Revenue Growth (YoY)
Growth
+59.9% +25.5% Higher Growth KMTS
Operating Margin (TTM)
Profitability
-134.5% -5894.3% Higher Margin KMTS
Net Profit Margin
Profitability
-140.4% 19861.4% Higher Margin DXR
Return on Equity (ROE)
Capital Efficiency
-73.7% 14.2% Higher ROE DXR
52-Week Range Position
Momentum
73% ($17–$32) 2% ($8–$15) Stronger Trend KMTS
Beta / 30D Volatility
Risk Regime
1.84β · 63% Vol 0.28β · 32% Vol Lower Realized Risk DXR
Unified Institutional Score
Composite Signal
43.8 / 100 (HOLD) 52.2 / 100 (HOLD) Higher Composite DXR
Trailing 12M Revenue (USD)
Operating Scale
$107M $31,360 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
53.9% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 15.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$117M ($53M Net Cash) N/A ($8.88 Book/Sh · 14.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KMTS +19.55 pp
KMTS: +2.68% · DXR: -16.87%
3M Horizon KMTS +20.49 pp
KMTS: +0.83% · DXR: -19.66%
6M Horizon KMTS +53.55 pp
KMTS: +36.11% · DXR: -17.44%
1Y Horizon KMTS +45.55 pp
KMTS: +12.28% · DXR: -33.27%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KMTS vs DXR. Trailing 12-month operating profitability (KMTS -134.5% vs DXR -5894.3%) and valuation multiples (KMTS N/M vs DXR 64.5x Forward P/E) are benchmarked directly in Pillar 4 below.

KMTS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$107M
Gross Margin53.9%
Op. Margin-134.5%
ROE / Fwd P/E-73.7% · N/M
DXR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$31,360
Gross Margin100.0%
Op. Margin-5894.3%
ROE / Fwd P/E14.2% · 64.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
KMTS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KMTS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DXR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DXR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
KMTS Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $1.7B market capitalization and -134.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DXR Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $49.5M market capitalization and -5894.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ KMTS vs DXR Key Questions & Quantitative Answers

As of Nov 16, 2026, Kestra Medical Technologies, Ltd. (KMTS) is the stronger overall head-to-head candidate over Daxor Corporation (DXR) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow). KMTS carries a Unified Composite Score of 43.8/100 (HOLD) at $27.97 (N/M Forward P/E, -134.5% operating margin), whereas DXR carries 52.2/100 (HOLD) at $8.36 (64.5x Forward P/E, -5894.3% operating margin). Composite vs. Pillar Nuance: While DXR currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. KMTS 43.8/100 HOLD), KMTS captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (-134.5% vs. -5894.3% operating margin) and revenue trajectory (+59.9% vs. +25.5% YoY). Technical & Structure Timing Caution: KMTS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.0); meanwhile DXR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KMTS leads the Growth & Scale pillar: KMTS posts +59.9% YoY revenue growth and +0.0% YoY earnings growth on $107M TTM revenue (53.9% gross margin, -134.5% operating margin), compared with DXR at +25.5% YoY revenue growth and +329.3% YoY earnings growth on $31,360 TTM revenue (100.0% gross margin, -5894.3% operating margin). On trailing 12-month operating scale, KMTS generates $107M in USD-normalized revenue versus $31,360 for DXR. In operating R&D and SG&A reinvestment, KMTS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DXR.

DXR screens cheaper on headline valuation multiples. KMTS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 15.5x EV/Revenue (-109.7% FCF margin), whereas DXR trades at 64.5x Forward P/E, 7.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KMTS (-73.7% ROE) versus DXR (14.2% ROE) capital efficiency.

In options market volatility and institutional positioning, KMTS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.84β · 63% Vol realized risk). By comparison, DXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.28β · 32% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.